Company profile

Dexcom

Relentless innovation from the leaders in glucose health

Chronic Disease Management & Digital TherapeuticsPublic stage

Company profile

About Dexcom

Dexcom is a pioneering medical technology company that has set the standard in glucose biosensing for over 25 years. The company develops innovative continuous glucose monitoring (CGM) systems that empower people to understand what is happening in their bodies in real time, helping them better manage diabetes and overall health. Dexcom's flagship products include the Dexcom G7 and G7 15 Day CGM systems, which deliver best-in-class accuracy and send glucose readings to smartphones or receivers every five minutes, and Stelo, the first over-the-counter glucose biosensor for adults not on insulin. These technologies help users understand how food, exercise, stress, and sleep affect their glucose levels, enabling better health decisions. Dexcom's systems integrate with a growing ecosystem of connected partners including insulin pumps, insulin pens and caps, automated insulin delivery algorithms, digital health apps, and wearable devices. The company serves people with all types of diabetes as well as individuals seeking to optimize their metabolic health. With a mission to transform how people worldwide track their glucose, Dexcom partners with healthcare providers, health systems, researchers, and forward-thinking organizations to expand access to life-changing glucose sensing technology. The company is committed to sustainability, advancing healthcare equity, and maintaining direct dialogue with customers through initiatives like the Dexcom Customer Advisory Council.

Company description Dexcom official website

Mission. Dexcom empowers people to take control of health through innovative glucose biosensing technology.

Primary marketChronic Disease Management & Digital Therapeutics
Commercial modelCommercial information available on request
Company presenceLinkedIn
Work at Dexcom?

Claim this profile to manage Company information and connect with the Health AI Central audience.

Claim this listing

01 · Operating footprint

Where the Company operates

Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.

Clinical focus

  • Diabetes (all types)
  • General glucose health monitoring
  • Glucose dysregulation
  • Prediabetes

Who it serves

  • Clinical Research organizations
  • Consumers with diabetes
  • Health Systems
  • Healthcare Professionals

Deployment & integration

Cloud Saas · Embedded deployment with recorded integration context.

Recorded integration context: AID (Automated Insulin Delivery) Algorithms, Connected Insulin Pens and Caps, Connected Insulin Pumps, Digital Health Apps, Health Systems Data Integrations, Wearable Devices.

Geographic context

MarketsInternational markets (reviewing partnerships outside US) · United States
Company sourceOfficial website

Company milestones

Platform expansion

Launched Stelo as first over-the-counter CGM (2024-2025). Introduced Dexcom G7 direct-to-watch feature. Formed Customer Advisory Council in January 2026. Celebrating 25+ years in glucose biosensing technology.

Partnerships

Recorded partners

  • Clinical research organizations
  • Connected insulin pump manufacturers
  • Digital health app developers
  • Health systems
  • Wearable device companies

02 · Flagship portfolio

Products, workflows, and platform capabilities

Selected source-backed Company products and the available commercial context.

Dexcom Clarity

Data analysis and reporting platform for glucose monitoring

Platform · Cloud SaaSCompany source

Dexcom Follow

Companion app for remote glucose monitoring

Software · Cloud SaaSCompany source

Dexcom G7

The world's most powerful CGM system with best-in-class accuracy

Device · EmbeddedCompany source

Dexcom G7 15 Day

Extended 15-day wear continuous glucose monitoring system

Device · EmbeddedCompany source

Dexcom Share

Remote glucose monitoring and sharing platform

Software · Cloud SaaSCompany source

Stelo Glucose Biosensor

First over-the-counter CGM for personalized glucose insights without prescription

Device · EmbeddedCompany source

03 · Research intelligence

Research Intelligence evidence

Publications, preprints, clinical validation, and regulatory records in Evidence Position order.

04 · Company-reported outcomes

Outcomes and case studies

Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.

Best-in-class accuracy

CGM system accuracy for glucose monitoring

73.9% sensor life

Sensors lasting full 15 days

Real-time glucose monitoring

5-minute reading intervals

Lance Bass

Personal glucose monitoring and diabetes management

Receives new glucose reading every 5 minutes, eliminating guesswork in glucose management

05 · Leadership

Leadership team

Leadership profiles and professional links from the current Company record.

Jake Leach

Jake Leach

President and Chief Executive Officer

LinkedIn

Sumi Shrishrimal, CPA, CISA

Vice President Internal Audit

LinkedIn

Matt Dolan

Executive Vice President, Strategy, Corporate Development & Dexcom Labs

LinkedIn

Sayron Ruiz

Vice President Operations

LinkedIn
bill Stack

bill Stack

Chief Technology Officer

LinkedIn
Jereme Sylvain

Jereme Sylvain

EVP, Chief Financial Officer

LinkedIn

06 · Company updates

Updates from Dexcom

Recent articles published on Dexcom's official website.

No Company updates are currently listed.

07 · HAIC coverage

Coverage and analysis

Health AI Central reporting that mentions this Company.

08 · Official presence

Company sources and channels

Curated official destinations from the active Company record.

09 · Market pathway

Additional Companies in this Market

Other active Companies in the same market, selected alphabetically from the HAIC directory.

Market context

Chronic Disease Management & Digital Therapeutics

Companies using AI and digital health tools to help patients manage chronic conditions through digital therapeutics, gamified health management, and AI-powered coaching. Covers management of all chronic diseases including diabetes, hypertension, COPD, heart disease, and multi-condition platforms. Includes continuous glucose monitoring (CGM) systems with AI analytics and insulin optimization algorithms.

Explore the full market directory or compare this Company with additional active profiles.

View all Companies in this market

10 · Pro research

Coming soon

Expanded Company research is in development.

Health AI Central Pro · Coming Soon

Deeper Company research is coming soon.

Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.

ResearchEvidence analysis

Linked research, clinical, and regulatory source pathways.

CompanyTechnical context

Expanded product, deployment, integration, and partnership research.

MethodSource & review record

Record-level provenance and review context.

Coming Soon